Healthcare

Entry rationale

At the dated reference price, the shares demand economics close to our optimistic scenario while leaving substantial downside under ordinary execution. This is a price objection, not an execution blocker; a meaningful discount to our modeled value would change the entry judgment.

Entry rationale

At the dated reference price, Lilly does not offer the entry discount our subjective scenario model requires for pricing, patent and execution risk. This is a price constraint, not an investment veto; a retreat below the model's buy threshold, with the operating thesis intact, would change the judgment.